Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Author:
Publisher
Massachusetts Medical Society
Subject
General Medicine
Link
http://www.nejm.org/doi/pdf/10.1056/NEJMsa1200223
Cited by 139 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022;eClinicalMedicine;2023-09
2. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology;JCO Oncology Practice;2023-07
3. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis;The Lancet Regional Health - Americas;2023-06
4. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan;Biological and Pharmaceutical Bulletin;2023-05-01
5. Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study;JRSM Open;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3